DOCSLIB.ORG

Ref Tender No: HLL/SD/CHO/2016-17/TENDER/009

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Ref Tender No: HLL/SD/CHO/2016-17/TENDER/009 AMENDMENT NO.4 Dated 03.04.2017 Ref Tender No: HLL/SD/CHO/2016-17/TENDER/009 The following amendments have been incorporated to the bid document for the above Tender for selecting external reference laboratory for outsourcing of laboratory tests including specialty clinical tests. Sl Parameters No Amended Tender Detail The following additional points are incorporated under the sub clause “Terms and Conditions. I. The TAT (Turnaround time) starts from the time of collecting the samples by the bidder lab from any of Hindlabs or its collection centres. II. TAT is going to be calculated as per the category /classification of cities by Government of India by the Office Memorandum of Department of Expenditure, Ministry of Finance vide number 2/5/2014-E II (B) dated 21-07-2015. (Copy of this order is enclosed for reference as serial no: 5 in this document.) III. The TAT given in the tender is directly applicable for tier X & Y cities. 1. IV. In the case of Z tier cities and other places, if the sample generation point of Hindlabs from where the bidder has to collect the samples are within 100 km from any of the tier X & Y cities then the TAT will be same as given in the tender V. In the case of Z tier cities and other places, if the sample generation point of Hindlabs from where the bidder has to collect the samples is within 100-250 Km away from any of the tier X & Y cities then additional 12 Hours can be given along with the TAT as per the tender. VI. In the case of Z tier cities and other places, if the sample generation point of Hindlabs from where the bidder has to collect the samples is above 250 Km away from any of the tier X & Y cities then additional 24 Hours can be given along with the TAT as per the tender. AMENDMENT NO.4 Dated 03.04.2017 Original Tender Detail As per page number 6 under sub clause Terms and conditions it is mentioned that " Bills for testing should be provided on a monthly basis with the actual rates as mentioned in the tender document (Rates after quoted percentage of discount) and the TAT details need to be incorporated in the Invoices for individual samples. If invoices are being produced as per the above requirement, payment will be made within 30 days from the receipt of the invoice." Amended tender Details This point shall be read as “Bills for testing should be provided on a monthly basis with 2 the actual rates as mentioned in the tender document (Rates after quoted percentage of discount) and the TAT details need to be incorporated in the Invoices for individual samples. If invoices are being produced as per the above requirement, payment will be made within 30 days from the receipt of the invoice. The payment to the bidder is based on the invoice generated and hence if there is any discrepancy in the bidder’s invoice the payment will be withheld. HLL will not be responsible for any delay in result dispatch of the investigation due to the withheld of the payment. In such circumstances bidder has to ensure that the sample processing and dispatch of the results are happening as per the allowed TAT. Otherwise HLL will deduct the payment as per the terms mentioned against TAT. If any variation of TAT due to the non-payment of HLL within the agreed time period, then the penalty clause for TAT will not be applicable.". Original Tender Detail As per page number 6 under sub clause Terms and conditions it is mentioned that “The outsourcing partner shall post a competent person wherever intimated irrespective of load by HLL for sample collection, sample dispatch, report dispatching and data entry activities.” 3. Amended tender Details This point shall be read as The outsourcing partner shall post a competent person wherever intimated irrespective of load by HLL for sample collection, sample dispatch, report dispatching and data entry activities. If the sample is not adequate/ insufficient or not fit to be tested then it should be intimated to Hindlabs or its collection centre while collecting the samples from there or at the time sample reaches the processing lab. The penalty clause will not be applicable for default samples, but the reasoning of the AMENDMENT NO.4 Dated 03.04.2017 same will be checked by Hindlabs authorities. The processing lab for each investigation for different locations will be revealed to Hindlabs by the bidder and thus at the time of signing the agreement the time taken to reach the processing lab can be derived. If the bidder fails to intimate this on time then the penalty clause will be imposed. The Annexure 4 of the existing tender document shall be replaced with the Annexure 4 as given Below. Amended tender Details ANNEXURE 4 TURN AROUND TIME Routine CGHS Investigations Requiring immediate reporting Tender list S. No AS PER Investigation Target TAT Annexure 3A Urine routine- pH, Specific gravity, sugar, protein and 1 microscopy 6 hours 4 2 Urine-Microalbumin 6 hours 3 Stool routine 6 hours 6 Stool occult blood 6 hours 8 Semen analysis 6 hours 9 Haemoglobin (Hb) 6 hours 10 Total Leucocytic Count (TLC) 6 hours 11 Differential Leucocytic Count (DLC) 6 hours 12 ESR 6 hours 13 Total Red Cell count with MCV,MCH,MCHC,DRW 6 hours Complete Haemogram/CBC, Hb,RBC count and indices, 14 6 hours TLC, DLC, Platelet, ESR, Peripheral smear examination 15 Platelet count 6 hours 16 Reticulocyte count 6 hours 17 Absolute Eosinophil count 6 hours 18 Packed Cell Volume (PCV) 6 hours 19 Peripheral Smear Examination 6 hours 20 Smear for Malaria parasite 6 hours AMENDMENT NO.4 Dated 03.04.2017 21 Bleeding Time 6 hours 26 Activated partial ThromboplastinTime (APTT) 6 hours 27 Rapid test for malaria(card test) 6 hours 38 Blood Group & RH Type 6 hours 39 Cross match 6 hours 40 Coomb’s Test Direct 6 hours 41 Coomb’s Test Indirect 6 hours 44 HBs Ag 6 hours 45 HCV 6 hours 46 HIV I and II 6 hours 47 VDRL 6 hours 49 Platelet Concentrate 6 hours 50 Random Donor Platelet(RDP) 6 hours 51 Single Donor Platelet (SDP- Aphresis) 6 hours 64 Blood Glucose Random 6 hours 65 24 hrs urine for Proteins,Sodium, creatinine 6 hours 66 Blood Urea Nitrogen 6 hours 67 Serum Creatinine 6 hours 68 Urine Bile Pigment and Salt 6 hours 69 Urine Urobilinogen 6 hours 70 Urine Ketones 6 hours 71 Urine Occult Blood 6 hours 72 Urine total proteins 6 hours 73 Rheumatoid Factor test 6 hours 74 Bence Jones protein 6 hours 75 Serum Uric Acid 6 hours 76 Serum Bilirubin total & direct 6 hours 77 Serum Iron 6 hours 78 C.R.P. 6 hours 79 C.R.P Quantitative 6 hours 80 Body fluid (CSF/Ascitic Fluid etc.)Sugar, Protein etc. 6 hours 81 Albumin. 6 hours 82 Creatinine clearance. 6 hours 83 Serum Cholesterol 6 hours 84 Total Iron Binding Capacity 6 hours 85 Glucose (Fasting & PP) 6 hours AMENDMENT NO.4 Dated 03.04.2017 86 Serum Calcium –Total 6 hours 87 Serum Calcium –Ionic 6 hours 88 Serum Phosphorus 6 hours 89 Total Protein Alb/Glo Ratio 6 hours 95 S.G.P.T. 6 hours 96 S.G.O.T. 6 hours 97 Serum amylase 6 hours 98 Serum Lipase 6 hours 99 Serum Lactate 6 hours 100 Serum Magnesium 6 hours 101 Serum Sodium 6 hours 102 Serum Potassium 6 hours 104 Anemia Profile 6 hours 107 Triglyceride 6 hours 108 Glucose Tolerance Test (GTT) 6 hours 110 CPK 6 hours 111 Foetal Haemoglobin (HbF) 6 hours 112 Prothrombin Time (P.T) 6 hours 113 LDH 6 hours 114 Alkaline Phosphatase 6 hours 115 Acid Phosphatase 6 hours 116 CK MB 6 hours 117 CK MB Mass 6 hours 118 Troponin I 6 hours 119 Troponin T 6 hours 120 Glucose Phosphate Dehydrogenase (G6PD) 6 hours 125 Feritin. 6 hours 126 Blood gas analysis 6 hours 127 Blood gas analysis with electrolytes 6 hours 128 Urine pregnancy test 6 hours 130 Hb A1 C 6 hours 132 Kidney Function Test. 6 hours 133 Liver Function Test. 6 hours 134 Lipid Profile (Total cholesterol,LDL,HDL,trigylcerides) 6 hours 137 Serum Ferritin 6 hours 146 LDL. 6 hours AMENDMENT NO.4 Dated 03.04.2017 151 Chloride. 6 hours 152 Magnesium. 6 hours 154 Lipase. 6 hours 179 T3, T4, TSH 6 hours 180 T3 6 hours 181 T4 6 hours 182 TSH 6 hours 185 Prolactin 6 hours 249 Osmolality urine 6 hours 250 Osmolality serum 6 hours 251 Urinary sodium 6 hours 252 Urinary Chloride 6 hours 253 Urinary potassium 6 hours Tender list S. No AS PER OTHER CGHS INVESTIGATION LIST Target TAT Annexure 3A 7 Post coital smear examination 2 days 22 Osmotic fragility Test 2 days 23 Bone Marrow Smear Examination 4 days 24 Bone Marrow Smear Examination with iron stain 4 days 25 Bone Marrow Smear Examination and cytochemistry 4 days 28 WBC cytochemistry for leukemia -Complete panel 4 days Bleeding Disorder panel- PT, APTT, Thrombin Time 29 Fibrinogen, D-Dimer/ FDP 3 days 30 Factor Assays-Factor VIII 3 days 31 Factor Assays-Factor IX 3 days Tests for hypercoagulable states- Protein C, Protein S, 33 Antithrombin 3 days 34 Tests for lupus anticoagulant 2 days Tests for Antiphospholipid antibody IgG, IgM (for 35 cardiolipin and B2 Glycoprotein 1) 3 days 32 Platelet Function test 3 days 36 Thalassemia studies (Red Cell indices and Hb HPLC) 3 days AMENDMENT NO.4 Dated 03.04.2017 37 Tests for Sickling / Hb HPLC) 1 day 42 3 cell panel- antibody screening for pregnant female 2 days 43 11 cells panel for antibody identification 4 days 48 RH Antibody titer 3 days 52 Routine-H & E 1 week 53 Special stain 1 week 54 Immunohistochemistry(IHC) 1 week 55 Frozen section 1 week 56 Paraffin section 1 week 57 Pap Smear 3 days 58 Body fluid for Malignant cells 2 days 59 FNAC 5 days 60 Leukemia panel /Lymphoma panel 3 days 61 PNH Panel-CD55,CD59 3 days 62 Karyotyping 2 weeks 63 FISH 10 days 65 24 hrs urine for Proteins,Sodium, creatinine 2 days 68 Urine Bile Pigment and Salt 2 days 77 Serum Iron 2 days 78 C.R.P.
Load more

Recommended publications
  • Dengue–COVID-19 Coinfection: the First Reported Case in the Philippines
    Case Report/Case Series Dengue–COVID-19 coinfection: the first reported case in the Philippines Angyap Saipen,a Bernard Demot,a Lowella De Leona Correspondence to Angyap Lyn Saipen (email: [email protected]) The rainy season in the Philippines is from June to October; this is when the number of dengue cases typically increases. In 2020 during this time, the world was facing the threat of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) infection. Coronavirus disease 2019 (COVID-19) and dengue viral infections have similar presentations and laboratory findings, including fever and thrombocytopenia, and there have been reports of coinfection with SARS-CoV-2 and arthropod-borne virus. Here, we report a case of SARS-CoV-2–dengue virus coinfection in the Philippines in a female aged 62 years, whose early symptom was fever and who was positive for SARS-CoV-2 and positive for dengue. Early recognition of such coinfection is important so that proper measures can be taken in the management of the patient. engue fever is a mosquito-borne viral infection fever (highest recorded at 39.5 °C), with associated found mostly in tropical climates, including headache (frontoparietal in location, rated 5/10 and Dthe Philippines. The clinical manifestations of bandlike in character) and retro-orbital pain, general- dengue may include high-grade fever, headache, retro- ized body ache, myalgia and arthralgia. There was no orbital pain, muscle and joint pains, and rashes. In associated nausea, vomiting or blurring of vision. The 2019, the Philippines had one of the highest numbers patient had pain over the ankle joints, with no associ- of reported dengue cases among countries in Asia ated warmth or limitation of movement, and no rashes, and South-East Asia.1 According to the World Health cough or dyspnoea.
    [Show full text]
  • VDL Annual Report
    2010 Annual Report Table of Contents ISU VDL Mission Statement .......................................................................................................................... 3 VDPAM Organizational Chart ....................................................................................................................... 4 VDPAM External Advisory Board .................................................................................................................. 5 VDL Faculty List ............................................................................................................................................ 6 VDL Staff List ................................................................................................................................................ 7 New Tests Introduced ................................................................................................................................... 9 2010 Statistical Data ................................................................................................................................... 10 Accessions .............................................................................................................................................. 10 Tests ....................................................................................................................................................... 11 Submission Trends ................................................................................................................................
    [Show full text]
  • 69292/2020/Estt-Ne Hr 5
    5 69292/2020/ESTT-NE_HR Index Sr. No. Particulars Page No. 1 General Billing Rules 2--11 2 Packages Detail 12--23 3 Room Rent 24--25 4 Consultation Charges. 26--32 5 CTVS PACKAGE ROCEDURES 33--35 6 CTVS PEDIATRIC 36--37 7 CATH ADULT PROCEDURES 38--39 8 EP STUDY PACKAGE PROCEDURES 40--41 9 PEDIATRIC CATH PROCEDURES 42--43 10 UROLOGY PROCEDURES 44--46 11 NEPHROLOGY PROCEDURES 47-52 12 VASCULAR SURGERY 53--54 13 GENERAL SURGERY PROCEDURE 55--62 14 NUEROLOGY PROCEDURES 63--67 15 UROLOGY 68--71 16 DENTAL PROCEDURES 72--78 17 DERMATALOGY PROCEDURES 79--82 18 ENT PROCEDURES 83--87 19 NEPHROLOGY 88--89 20 GYNECOLOGY PROCEDURES 90--93 21 LABORATORY TEST CHARGES 94-120 22 ONCOLOGY PROCEDURES 121-126 23 OPTHALMOLOGY PROCEDURES 127-130 24 PULMONOLOGY PROCEDURES 131-134 25 PAIN CLINIC CHARGES 135-136 26 PLASTIC SURGERY 137-141 27 PHYSIOTHERAPY CHARGES 142-144 28 MISC. & OTHER SERVICES 145-148 29 CARDIAC DIAGNOSTIC CHARGES 149-151 30 CT PROCEDURES 152-155 31 MRI PROCEDURES 156-162 32 X RAY PROCEDURES 163-166 33 ULTRASOUND PROCEDURES 167-169 34 DIAGNOSTIC NEUROLOGY 170-172 35 DIANG-HIS 173-174 36 BLOOD BANK 175-176 37 GASTROENTEROLOGY PACKAGES 177-178 38 GASTROENTEROLOGY 179-184 39 TRANSPLANT CHARGES 185-186 0 6 69292/2020/ESTT-NE_HR 40 ORTHOPAEDIC PACKAGES 187-189 41 ORTHOPAEDICS PROCEDURES 190-199 42 MAXILLOFACIAL SURGERY 200-206 43 ONCO SURGERY 207-209 44 INTERVENTIONAL RADIOLOGY & CARDIOLOGY 210-211 45 ANESTHESIA PROCEDURES 212-214 46 PSYCHOLOGY 215-216 1 7 69292/2020/ESTT-NE_HR GENERAL BILLING RULES & GUIDELINES 2 8 69292/2020/ESTT-NE_HR Registration and Admission Charges a) Onetime Registration charges of INR.100/- shall be charged to all new patients coming to Hospital for the first time.
    [Show full text]
  • Severe Dengue Due to Secondary Hemophagocytic Lymphohistiocytosis
    IDCases 8 (2017) 50–53 Contents lists available at ScienceDirect IDCases journal homepage: www.elsevier.com/locate/idcr Case report Severe dengue due to secondary hemophagocytic lymphohistiocytosis: A case study Ujjwayini Ray*, Soma Dutta, Susovan Mondal, Syamasis Bandyopadhyay Apollo Gleneagles Hospitals, 58, Canal Circular Road, Kolkata 70054, West Bengal, India A R T I C L E I N F O A B S T R A C T Article history: Received 17 March 2017 Dengue, transmitted by the mosquito Aedes aegypti affects millions of people worldwide every year. Received in revised form 25 March 2017 Dengue induced hemophagocytic lymphohistiocytosis (HLH) is a serious condition and may prove fatal if Accepted 25 March 2017 not detected early and treated appropriately. Diagnosis of HLH is challenging and usually missed as Available online xxx clinical and laboratory findings are nonspecific. Moreover, the pathophysiology of the systemic inflammatory response syndrome and/or sepsis is remarkably similar to HLH. Secondary HLH following Keywords: infection by the dengue virus is now being increasingly recognized as a cause of severe form of the Bicytopenia disease. We report a case of dengue associated HLH in an otherwise healthy person who deteriorated Dengue during the course of hospitalization. A disproportionately high ferritin level and persistent bicytopenia Hemophagocytic lymphohistiocytosis prompted investigations for HLH. Diagnosis of dengue fever with virus-associated hemophagocytic (HLH) Infection syndrome was established according to the diagnostic criteria laid down by the Histiocyte Society. We discuss the diagnosis and management of this complex case and try to generate awareness about dengue Intravenous immunoglobulin G induced HLH as one of the possible causes for severe manifestations of this infection © 2017 The Authors.
    [Show full text]
  • Flavivirus Cross-Reactivity to Dengue Nonstructural Protein 1 Antigen Detection Assays
    diagnostics Article Flavivirus Cross-Reactivity to Dengue Nonstructural Protein 1 Antigen Detection Assays Li Kiang Tan 1, Wing Yan Wong 1, Hui Ting Yang 1, Roland G. Huber 2 , Peter J. Bond 2,3, Lee Ching Ng 1,4, Sebastian Maurer-Stroh 2,3 and Hapuarachchige Chanditha Hapuarachchi 1,* 1 Environmental Health Institute, National Environment Agency, Singapore 38667, Singapore; [email protected] (L.K.T.); [email protected] (W.Y.W.); [email protected] (H.T.Y.); [email protected] (L.C.N.) 2 Bioinformatics Institute, Agency for Science, Technology and Research, Singapore 138671, Singapore; [email protected] (R.G.H.); [email protected] (P.J.B.); [email protected] (S.M.-S.) 3 Department of Biological Sciences, National University of Singapore, Singapore 117558, Singapore 4 School of Biological Sciences, Nanyang Technological University, Singapore 639798, Singapore * Correspondence: [email protected]; Tel.: +65-65115335; Fax: +65-65115339 Received: 7 November 2019; Accepted: 23 December 2019; Published: 24 December 2019 Abstract: Dengue virus (DENV) and Zika virus (ZIKV) are flaviviruses of public health relevance. Both viruses circulate in the same endemic settings and acute infections generally manifest similar symptoms. This highlights the importance of accurate diagnosis for clinical management and outbreak control. One of the commonly used acute diagnostic markers for flaviviruses is nonstructural protein 1 (NS1). However, false positives due to antigenic cross-reactivity have been reported between DENV and ZIKV infections when using DENV NS1 antigen (NS1 Ag) detection assays in acute cases. Therefore, we investigated the lowest detectable virus titres and cross-reactivity of three commercial dengue NS1 Ag rapid assays and two ELISAs for different flaviviruses.
    [Show full text]
  • Detection of NS1 Antigen in Serologically Confirmed Dengue Cases at Least After 5 Days of Infection
    Research Article Anatomy Physiol Biochem Int J Volume 4 Issue 2- February 2018 Copyright © All rights are reserved by Sudipta Poddar DOI: 10.19080/APBIJ.2017.04.555632 Detection of NS1 Antigen in Serologically Confirmed Dengue Cases at least after 5 Days of Infection Sudipta Poddar* and Amiya Kumar Hati Department of Medical Physiology, Lincoln University College, Malaysia Submission: January 01, 2017; Published: February 09, 2018 *Corresponding author: Sudipta Poddar, Department of Medical Physiology, Lincoln University College, 47301, Petaling Jaya, Malaysia; Email: Abstract Objectives: The objective of this paper is to detect the NS1 antigen beyond 5 days of infection in serologically confirmed dengue cases in whom both NS1 antigen and IgG and IgM antibodies were assessed. Methods: Out of a total of 1037 suspected persons 257 i.e. 24.78% were dengue reactive in 2013 and 2014. Dengue cases were diagnosed in the laboratory from suspected patients by dengue specific IgG, IgM antibodies and NS1 antigen. NS1 antigen and IgG antibodies were monitored in 220 (194+26) suspected dengue cases where interpretation was possible to detect NS1 beyond 5 days of infection. This study of detection of NS1 antigen in serologically confirmed dengue cases at least after 5 days of infection. Results: Among this 220 cases 86 (80+6) were confirmed dengue cases. Out of these 86 cases NS1 antigen was found beyond 5 days of infection in 15 i.e. 17.44%. Conclusion: It would be reasonable to believe that many such cases would be found in the category I where only NS1 was tested. Hence for getting the information on NS1 antigen beyond 5 days all three serological tests (NS1 antigen, IgG and IgM antibodies) should be performed.
    [Show full text]
  • The Point-Of-Care Diagnostic Landscape for Sexually Transmitted Infections (Stis)
    The Point-of-Care Diagnostic Landscape for Sexually Transmitted Infections (STIs) Maurine M. Murtagh The Murtagh Group, LLC 2019 1 Introduction Sexually transmitted infections (STIs) continue to be a significant global public health issue, with an estimated 378 million people becoming ill in 2016 with one of 4 STIs: syphilis, Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Trichomonas vaginalis (TV) (1) . In addition, more than 291 million women have a human papillomavirus (HPV) infection, which is a necessary cause of high grade cervical intraepithelial neoplasia (grade 2 or higher [CIN2+]) (1). This report considers the available and pipeline diagnostics for curable STIs, namely syphilis, CT, NG, TV, and HPV. With some exceptions, the existing diagnostics for these STIs are laboratory-based platforms, which typically require strong infrastructure and well-trained laboratory technicians. In addition, test turnaround time (TAT) is often long, requiring patients to return for test results on a subsequent clinic visit. This, in turn, leads to significant loss to follow-up. Therefore, while these laboratory-based diagnostics are effective, they may not always be suitable for use in resource-limited settings where diagnostic access and delivery are difficult. There are now a variety of tests available for use at or near the point of patient care (POC) for STIs (2). These include a wide range of rapid diagnostic tests (RDTs) for human immunodeficiency virus (HIV), hepatitis C virus (HCV) and syphilis, among others, with which it is possible to detect infection using fingerprick blood, or in some cases, oral fluid.1 In addition, other types of POC tests, including simple molecular tests for use in primary healthcare settings, have also become available recently.
    [Show full text]
  • The Point-Of-Care Diagnostic Landscape for Sexually Transmitted Infections (Stis)
    The Point-of-Care Diagnostic Landscape for Sexually Transmitted Infections (STIs) Maurine M. Murtagh The Murtagh Group, LLC 31 May 2018 1 Sexually transmitted infections (STIs) continue to be a significant global public health issue, with an estimated 357 million people becoming ill each year with one of 4 STIs: syphilis, Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Trichomonas vaginalis (TV) (1). In addition, more than 290 million women have a human papillomavirus (HPV), which infection is a necessary cause of high grade cervical intraepithelial neoplasia (grade 2 or higher [CIN2+]) (1). This report considers the available and pipeline diagnostics for curable STIs, namely syphilis, CT, NG, TV, and HPV. With some exceptions, the existing diagnostics for these STIs are laboratory-based platforms, which typically require strong laboratory infrastructure and well-trained laboratory technicians. In addition, test turnaround time is often long, requiring patients to return for test results on a subsequent clinic visit. This, in turn, leads to significant loss to follow-up. Therefore, while these laboratory-based diagnostics are effective, they may not always be suitable for use in resource-limited settings where diagnostic access and delivery are difficult. There are now a variety of tests available for use at or near the point of patient care (POC) for STIs (2). These include a wide range of rapid diagnostic tests (RDTs) for human immunodeficiency virus (HIV), hepatitis C virus and syphilis, among others, with which it is possible to detect infection using fingerprick blood, or in some cases, oral fluid.1 In addition, other types of POC tests, including simple molecular tests for use in primary healthcare settings, have also become available recently.
    [Show full text]
  • Design and Development of Small Molecule Based Biosensors for Detection of Pathogens
    Georgia State University ScholarWorks @ Georgia State University Chemistry Dissertations Department of Chemistry Fall 12-3-2018 Design and development of small molecule based biosensors for detection of pathogens Amrita Das Amrita Das Follow this and additional works at: https://scholarworks.gsu.edu/chemistry_diss Recommended Citation Das, Amrita, "Design and development of small molecule based biosensors for detection of pathogens." Dissertation, Georgia State University, 2018. https://scholarworks.gsu.edu/chemistry_diss/159 This Dissertation is brought to you for free and open access by the Department of Chemistry at ScholarWorks @ Georgia State University. It has been accepted for inclusion in Chemistry Dissertations by an authorized administrator of ScholarWorks @ Georgia State University. For more information, please contact [email protected]. i DESIGN AND DEVELOPMENT OF SMALL MOLECULE BASED BIOSENSORS FOR DETECTION OF PATHOGENS by AMRITA DAS Under the Direction of Suri S Iyer. Ph.D. i ii ABSTRACT Glycans are present on the cell surface of mammalian cells. In Dr. Iyer’s laboratories, we aim to understand the interactions of cell surface glycans with toxins and pathogens at a molecular level and use that information to develop a point of care diagnostics. This thesis primarily focuses on the development of new technologies that could potentially be further developed towards the point of care diagnostics. Chapter 1, the introduction chapter focuses on the biosensors, different recognition molecules, various reporters, techniques, testing parameters used in biosensors and point of care testing (POCT). In chapter 2, the focus is on the development of a novel electrochemical assay that uses repurposed glucose meters for the detection of different analytes.
    [Show full text]
  • Brochure Design 2020 04 15 V2
    D I S C O V E R Rapid Assays Rapid Reliable Expedient T E S T, D I A G N O S E & T R E A T RAPI DAS SAYS ImmunoScience India Pvt. Ltd. Gat No. 41, Village Kusgaon, Shivapur-Velhe Road, Taluka: Bhor, Pune 412205 Maharashtra, India An ISO 9001:2015 and ISO 13485:2016 Company [email protected] OUR NEWEST ADDITION ImmunoQuick Covid-19 IgM/IgG Rapid test for the detection of IgM and IgG antibodies in serum or plasma. Tested by National Institute of Virology, Pune. ImmunoQuick One StepPregnancy Pregnancy Test Device / Dipstick Intended Use : ImmunoQuick Pregnancy, est Pregnancy evice immunoassay for the rapid and visual determination of hCG (human Chorionic D O p Pregnancy T Pregnancy p n e te S te p S ne P D O r e e Pregnancy vic g Gonadotropin) hormone in human urine specimen to aid in the early detection of n e a n c y T e s t pregnancy. Two Formats ISO 9001 : 2015 ISO 13485 : 2016 } Certified Company est 25 One Step Procedure - T cy Pregnancy regnan Dipstick O n Fast - e P tep S - Device (Cassette) and Dipstick (Strip) te p S ne P D O ip r e Pregnancy s g tic n a k n c Duration - Result as early as 30 Seconds y T e One step pregnancy test is a self testing st Clear Results - 5 minutes Easy to use, ISO 9001 : 2015 } Certified Company ISO 13485 : 2016 Early detection - 25 High Sensitivity - Easy to interpret with clear test andSample dark control dropper bands provided with device format.
    [Show full text]
  • Dengue–COVID-19 Coinfection
    COVID-19: Case Report/SeriesArticle type Dengue–COVID-19 coinfection: the first reported case in the Philippines Angyap Saipen,a Bernard Demot,a Lowella De Leona Correspondence to Angyap Lyn Saipen (email: [email protected]) The rainy season in the Philippines is from June to October; this is when the number of dengue cases typically increases. In 2020 during this time, the world was facing the threat of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) infection. Coronavirus disease 2019 (COVID-19) and dengue viral infections have similar presentations and laboratory findings, including fever and thrombocytopenia, and there have been reports of coinfection with SARS-CoV-2 and arthropod-borne virus. Here, we report a case of SARS-CoV-2–dengue virus coinfection in the Philippines in a female aged 62 years, whose early symptom was fever and who was positive for SARS-CoV-2 and positive for dengue. Early recognition of such coinfection is important so that proper measures can be taken in the management of the patient. engue fever is a mosquito-borne viral infection fever (highest recorded at 39.5 °C), with associated found mostly in tropical climates, including headache (frontoparietal in location, rated 5/10 and Dthe Philippines. The clinical manifestations of bandlike in character) and retro-orbital pain, general- dengue may include high-grade fever, headache, retro- ized body ache, myalgia and arthralgia. There was no orbital pain, muscle and joint pains, and rashes. In associated nausea, vomiting or blurring of vision. The 2019, the Philippines had one of the highest numbers patient had pain over the ankle joints, with no associ- of reported dengue cases among countries in Asia ated warmth or limitation of movement, and no rashes, and South-East Asia.1 According to the World Health cough or dyspnoea.
    [Show full text]
  • Sd Product Catalog
    SD PRODUCT CATALOG Ordering When you place an order, please inform us of full description, product catalog number, unit size, quantity required including any special instructions with the correct billing and shipping address. Please note that individual products may have different specifications in various markets. Also, some products may not be available in all markets worldwide, only in selected markets. Standard Diagnostics, Inc. 65, Borahagal-ro, Giheung-gu, Yongin-si, Gyeonggi-do, Republic of Korea Tel No. : +82-31-899-2800 Fax No. : +82-31-899-2840 E-Mail : [email protected] Cancellation Any order cancellation should be informed to us within 2 days after placing purchase order. Special custom or large volume orders can not be cancelled at our sole discretion. Pricing Prices will be quoted upon request in US Dollars and are subject to change without prior notice. Quantity discounts are available for bulk. Payment Terms All orders are prepaid unless prior credit arrangements have been made with our Finance Department. All orders are F.O.B. from our factory. Freight charges and insurance charges are the responsibility of the customer. Prices are subject to change without prior notice. Shipping Shipments are made on FCA basis unless otherwise specified. The cost of courier service and special handling if requested shall be the customer’s responsibility. Please specify your shipping requirements when placing your order. Returned Goods Policy No returns shall be accepted without prior approval from SD in the form of an assigned Return Goods Authorization (RGA) Number. To return unused products in error sent to you, please contact us for a RGA Number and further details.
    [Show full text]